Home Stock

Stock Research: Takeda Pharmaceutical

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Takeda Pharmaceutical

TYO:4502 JP3463000004
34
  • Value
    70
  • Growth
    51
  • Safety
    Safety
    6
  • Combined
    33
  • Sentiment
    59
  • 360° View
    360° View
    34
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Takeda Pharmaceutical Co Ltd is a pharmaceutical company focused on research, development, and sale of pharmaceuticals. It focuses on gastrointestinal diseases, rare diseases, oncology, and neuroscience. The company operates in Japan, the United States, Europe, and China. In the last fiscal year, the company had a market cap of $46758 million, profits of $20016 million, and revenue of $30554 million, with 47455 employees.

more

ANALYSIS: With an Obermatt 360° View of 34 (better than 34% compared with alternatives), overall professional sentiment and financial characteristics for the stock Takeda Pharmaceutical are below the industry average. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Takeda Pharmaceutical. The consolidated Value Rank has an attractive rank of 70, which means that the share price of Takeda Pharmaceutical is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 70% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 51, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 59. But the company’s financing is risky with a Safety rank of 6. This means 94% of comparable companies have a safer financing structure than Takeda Pharmaceutical. ...read more

more
Strongest Rank Revenue Growth
Weakest Rank Dividend Yield
Country Japan
Industry Pharmaceuticals
Size XX-Large
Website takeda.com
Index
TOPIX 100
Nikkei 225
Takeda Pharmaceutical stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 9-Apr-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
70 80 74 95
Growth
51 32 3 11
Safety
Safety
6 7 6 8
Sentiment
59 30 8 8
360° View
360° View
34 24 6 7
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
32 33 33 37
Opinions Change
65 83 24 50
Pro Holdings
n/a 24 14 32
Market Pulse
39 28 20 19
Sentiment
59 30 8 8
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
70 80 74 95
Growth
51 32 3 11
Safety Safety
6 7 6 8
Combined
33 18 6 26
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
50 72 64 76
Price vs. Earnings (P/E)
7 26 30 71
Price vs. Book (P/B)
78 83 73 87
Dividend Yield
99 93 98 96
Value
70 80 74 95
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
5 8 15 11
Profit Growth
99 23 6 14
Capital Growth
28 68 21 37
Stock Returns
73 60 49 65
Growth
51 32 3 11
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
22 14 7 4
Refinancing
20 19 11 25
Liquidity
45 16 22 18
Safety Safety
6 7 6 8

Similar Stocks

Discover high‑ranked alternatives to Takeda Pharmaceutical and broaden your portfolio horizons.

Kinden

TYO:1944
Country: Japan
Industry: Construction & Engineering
Size: X-Large
Full Stock Analysis

Shionogi

TYO:4507
Country: Japan
Industry: Pharmaceuticals
Size: X-Large
Full Stock Analysis

Fuji Seal International

TYO:7864
Country: Japan
Industry: Metal & Glass Containers
Size: Medium
Full Stock Analysis

Daiwabo Holdings

TYO:3107
Country: Japan
Industry: Technology Distributors
Size: Large
Full Stock Analysis

Frequently Asked
Questions

This is a high-quality, high-growth stock with positive sentiment. However, the financing is on the riskier side. It is best for a growth-focused investor willing to accept higher financial risk for potentially higher shareholder returns.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews